PE20021098A1 - CD44v6 SPECIFIC ANTIBODIES - Google Patents

CD44v6 SPECIFIC ANTIBODIES

Info

Publication number
PE20021098A1
PE20021098A1 PE2002000422A PE2002000422A PE20021098A1 PE 20021098 A1 PE20021098 A1 PE 20021098A1 PE 2002000422 A PE2002000422 A PE 2002000422A PE 2002000422 A PE2002000422 A PE 2002000422A PE 20021098 A1 PE20021098 A1 PE 20021098A1
Authority
PE
Peru
Prior art keywords
refers
antibody
specific antibodies
proteins
sequence
Prior art date
Application number
PE2002000422A
Other languages
Spanish (es)
Inventor
Gunther Adolf
Karl-Heinz Heider
John J Miglietta
Dongen Augustinus Antonjus Maria Silvester Van
Erik Patzelet
Marlies Sproll
Elinborg Ostermann
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Int
Publication of PE20021098A1 publication Critical patent/PE20021098A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A ANTICUERPOS CON UNA SECUENCIA ESPECIFICA, QUE SON ESPECIFICOS DE UN EPITOPO QUE ESTAN CODIFICADOS POR EL EXON v6 VARIANTE DEL GEN CD44 Y A DERIVADOS DE DICHO ANTICUERPO. SE REFIERE TAMBIEN A MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN DICHAS PROTEINAS ANTICUERPO. LA MOLECULA DE ANTICUERPO COMPRENDE UNA REGION VARIABLE DE LA CADENA PESADA CARACTERIZADA POR LA SECUENCIA DE AMINOACIDOS DEFINIDA EN LA SEQ ID No. 1 O UNO DE SUS FRAGMENTOS, VARIANTES ALELICAS, VARIANTES FUNCIONALES, GLICOSILACION, DERIVADOS QUIMICOS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS PROTEINAS SIENDO UTILES PARA EL TRATAMIENTO DEL CANCERIT REFERS TO ANTIBODIES WITH A SPECIFIC SEQUENCE, WHICH ARE SPECIFIC TO AN EPITOPE THAT ARE CODED BY THE EXON v6 VARIANT OF THE CD44 GENE AND TO DERIVATIVES OF SUCH ANTIBODY. IT ALSO REFERS TO NUCLEIC ACID MOLECULES THAT CODE SUCH ANTIBODY PROTEINS. THE ANTIBODY MOLECULA INCLUDES A VARIABLE REGION OF THE HEAVY CHAIN CHARACTERIZED BY THE SEQUENCE OF AMINO ACIDS DEFINED IN SEQ ID No. 1 OR ONE OF ITS FRAGMENTS, ALLELIC VARIANTS, FUNCTIONAL VARIANTS, GLYCOSILATION, CHEMICAL DERIVATIVES. IT ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH PROTEINS BEING USEFUL FOR THE TREATMENT OF CANCER

PE2002000422A 2001-05-18 2002-05-17 CD44v6 SPECIFIC ANTIBODIES PE20021098A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
PE20021098A1 true PE20021098A1 (en) 2003-02-11

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000422A PE20021098A1 (en) 2001-05-18 2002-05-17 CD44v6 SPECIFIC ANTIBODIES

Country Status (18)

Country Link
EP (1) EP1397387A1 (en)
JP (1) JP2005504517A (en)
CN (1) CN1541226A (en)
AR (1) AR036154A1 (en)
BR (1) BR0210905A (en)
CA (1) CA2443437A1 (en)
CZ (1) CZ20033476A3 (en)
EA (1) EA200301169A1 (en)
EC (1) ECSP034838A (en)
EE (1) EE200300569A (en)
HU (1) HUP0400030A3 (en)
MX (1) MXPA03010523A (en)
PE (1) PE20021098A1 (en)
PL (1) PL365735A1 (en)
SK (1) SK15592003A3 (en)
WO (1) WO2002094879A1 (en)
YU (1) YU91403A (en)
ZA (1) ZA200307365B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1716179A2 (en) * 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
DK2167038T3 (en) * 2007-06-13 2018-08-06 Zymogenetics Inc USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
JP5763105B2 (en) 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Monoclonal antibody against CD44 used for the treatment of squamous cell carcinoma of the head and neck
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (en) * 2016-06-15 2017-12-21 李翀 Human endometrial cancer marker, antibody, and application of antibody
CN107556388A (en) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2149635A1 (en) * 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (en) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA

Also Published As

Publication number Publication date
BR0210905A (en) 2004-06-08
YU91403A (en) 2006-05-25
CN1541226A (en) 2004-10-27
WO2002094879A1 (en) 2002-11-28
EP1397387A1 (en) 2004-03-17
AR036154A1 (en) 2004-08-18
EE200300569A (en) 2004-04-15
SK15592003A3 (en) 2004-06-08
JP2005504517A (en) 2005-02-17
HUP0400030A2 (en) 2004-04-28
ECSP034838A (en) 2003-12-24
CZ20033476A3 (en) 2004-05-12
ZA200307365B (en) 2004-05-10
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
MXPA03010523A (en) 2004-07-01
EA200301169A1 (en) 2004-06-24
CA2443437A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
PE20021098A1 (en) CD44v6 SPECIFIC ANTIBODIES
CY1118467T1 (en) HIGH CONCENTRATION OF ANTIBODIES AND PROTEIN PACKAGES
ATE382053T1 (en) SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS
PE20070684A1 (en) RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
GB0315450D0 (en) Biological products
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
HK1158218A1 (en) Il-1beta binding antibodies and fragments thereof il-1
EP1067182A3 (en) Secretory protein or membrane protein
ATE510011T1 (en) NEW FUNGAL PROTEINS AND THE NUCLEIC ACIDS THAT ENCOD THEM
DK1548032T3 (en) KDR peptides and vaccines containing them
BRPI0616712B8 (en) method for amidating polypeptides with basic amino acid c-termini by specific endoproteases
DK1534830T3 (en) A vito-peptide expression library
ATE394484T1 (en) SMAD 6 AND ITS APPLICATIONS
ES2085993T3 (en) PROTEIN ASSOCIATED WITH ACUTE PANCREATITIS, MEANS FOR THE DIAGNOSIS OF ACUTE PANCREATITIS.
CY1106070T1 (en) POLYMORPHIMS IN THE HUMAN ORGANIC ANION TRANSPORTER C GENE (OATP-C) - (ORGANIC ANION TRANSPORTER C GENE)
CY1110848T1 (en) NOGO HUMAN ANTI-ANTIQUE AND THE PHARMACEUTICAL OF THE USE
CY1109207T1 (en) ECHINOCANDINI PROCEDURE
CY1114526T1 (en) PROTEASE CONSTRUCTION PROTEINS AND USE OF THESE
DE60122562D1 (en) NUCLEIC ACIDS CODED FOR STICHODACTYLIDAE CHROMOPROTEINS
DK1485481T3 (en) Fluorescent protein from Aequorea Coerulescens and uses thereof
DK1576157T3 (en) Fluorescent proteins from Copepode species and methods for using the same
MXPA05007940A (en) Compositions and methods for treating cancer using igsf9 and liv-1.
CO4520255A1 (en) TUMOR THERAPY THROUGH LYMPHOCYTES T CYTOTOXIC TRANSFER ADOPTIVES SPECIFIC CD44V
ATE328082T1 (en) SHORTENED BARD1 PROTEIN AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
TH78296A (en) Antibodies to OPGL

Legal Events

Date Code Title Description
FC Refusal